With 1.33 million shares changed hands, the volume of the stock remained lighter than its average volume of 9.95 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.32 whereas the lowest price it dropped to was $2.63. The 52-week range on THAR shows that it touched its highest point at $9.08 and its lowest point at $0.95 during that stretch. It currently has a 1-year price target of $5.00. Beta for the stock currently stands at 1.47.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of THAR was up-trending over the past week, with a rise of 10.45%, but this was down by -61.61% over a month. Three-month performance surged to 78.31% while six-month performance rose 102.74%. The stock gained 45.81% in the past year, while it has gained 4.23% so far this year.
Float and Shares Shorts:
At present, 4.22 million THAR shares are outstanding with a float of 2.16 million shares on hand for trading. On 2025-08-29, short shares totaled 0.64 million, which was 1207.99996 higher than short shares on 1753920000. In addition to Mr. Sireesh Appajosyula Pharm.D. as the firm’s CEO & Director, Mr. Vincent LoPriore serves as its Executive Chairman of the Board.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, THAR reported revenue of $0.0 and operating income of -$1851160.0. The EBITDA in the recently reported quarter was -$1848992.0 and diluted EPS was -$0.64.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for THAR since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$7.925 being high and -$7.925 being low. For THAR, this leads to a yearly average estimate of -$7.925.
